POINT Biopharma Global Inc. (PNT) Reports Q4 EPS of $1.53

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to POINT Biopharma Global Inc. (PNT) Reports Q4 EPS of $1.53

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

March 27, 2023 8:00 AM EDT

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates

Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023

INDIANAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

... More